Publicacións en colaboración con investigadores/as de Instituto de Investigación Sanitaria Fundación Jiménez Díaz (19)

2024

  1. Restored glyoxylate metabolism after AGXT gene correction and direct reprogramming of primary hyperoxaluria type 1 fibroblasts

    iScience, Vol. 27, Núm. 4

2023

  1. A human genome editing–based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features

    Blood, Vol. 142, Núm. 20, pp. 1752-1756

  2. Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T-ALL

    British Journal of Haematology

  3. Mitigation of peanut allergenic reactivity by combined processing: Pressured heating and enzymatic hydrolysis

    Innovative Food Science and Emerging Technologies, Vol. 86

  4. The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 878-895

2022

  1. A Novel PiRNA Enhances CA19-9 Sensitivity for Pancreatic Cancer Identification by Liquid Biopsy

    Journal of Clinical Medicine, Vol. 11, Núm. 24

  2. Biallelic germline mutations in MAD1L1 induce a syndrome of aneuploidy with high tumor susceptibility

    Science Advances, Vol. 8, Núm. 44

2021

  1. PD-L1 expression in peripheral T-cell lymphomas is not related to either PD-L1 gene amplification or rearrangements

    Leukemia and Lymphoma, Vol. 62, Núm. 7, pp. 1648-1656

2018

  1. A comprehensive study of calcific aortic stenosis: From rabbit to human samples

    DMM Disease Models and Mechanisms, Vol. 11, Núm. 6

2017

  1. Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer

    Oncotarget, Vol. 8, Núm. 25, pp. 40169-40180

2016

  1. C-Jun N-terminal kinase inactivation by mitogen-activated protein kinase phosphatase 1 determines resistance to taxanes and anthracyclines in breast cancer

    Molecular Cancer Therapeutics, Vol. 15, Núm. 11, pp. 2780-2790

2015

  1. Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer

    Clinical Cancer Research, Vol. 21, Núm. 2, pp. 347-356

  2. PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects

    Oncotarget, Vol. 6, Núm. 6, pp. 4299-4314

  3. Pyrosequencing-based assays for rapid detection of HER2 and HER3 mutations in clinical samples uncover an E332E mutation affecting HER3 in retroperitoneal leiomyosarcoma

    International Journal of Molecular Sciences, Vol. 16, Núm. 8, pp. 19447-19457

2014

  1. Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer

    Oncotarget, Vol. 5, Núm. 1, pp. 196-210

  2. Deregulation of miR-200b, miR-200c and miR-429 indicates its potential relevant role in patients with colorectal cancer liver metastasis

    Journal of Surgical Oncology

  3. Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1842, Núm. 9, pp. 1823-1829

  4. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential

    Molecular Cancer Therapeutics, Vol. 13, Núm. 4, pp. 938-947

  5. Re: Role of oncogenic K-ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling

    Journal of the National Cancer Institute